BRPI1012004A2 - "forma farmacêutica" - Google Patents
"forma farmacêutica"Info
- Publication number
- BRPI1012004A2 BRPI1012004A2 BRPI1012004A BRPI1012004A BRPI1012004A2 BR PI1012004 A2 BRPI1012004 A2 BR PI1012004A2 BR PI1012004 A BRPI1012004 A BR PI1012004A BR PI1012004 A BRPI1012004 A BR PI1012004A BR PI1012004 A2 BRPI1012004 A2 BR PI1012004A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical form
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0909680.1A GB0909680D0 (en) | 2009-06-05 | 2009-06-05 | Dosage form |
| PCT/GB2010/050948 WO2010140007A2 (en) | 2009-06-05 | 2010-06-07 | Dosage form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1012004A2 true BRPI1012004A2 (pt) | 2016-05-10 |
Family
ID=40936947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1012004A BRPI1012004A2 (pt) | 2009-06-05 | 2010-06-07 | "forma farmacêutica" |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9814679B2 (https=) |
| EP (1) | EP2437729B1 (https=) |
| JP (1) | JP5635082B2 (https=) |
| KR (1) | KR101816130B1 (https=) |
| CN (2) | CN102481260A (https=) |
| AU (1) | AU2010255502B2 (https=) |
| BR (1) | BRPI1012004A2 (https=) |
| CA (1) | CA2764517C (https=) |
| EA (1) | EA022801B1 (https=) |
| ES (1) | ES2713957T3 (https=) |
| GB (1) | GB0909680D0 (https=) |
| IL (1) | IL216748A0 (https=) |
| MX (1) | MX2011012929A (https=) |
| MY (1) | MY173629A (https=) |
| NZ (1) | NZ596879A (https=) |
| SG (2) | SG176304A1 (https=) |
| WO (1) | WO2010140007A2 (https=) |
| ZA (1) | ZA201109221B (https=) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1429744A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Morphine polymer release system |
| US20040234602A1 (en) | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| WO2004084868A1 (en) | 2003-03-26 | 2004-10-07 | Egalet A/S | Morphine controlled release system |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE102004032051A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| US8821928B2 (en) | 2007-06-04 | 2014-09-02 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
| AU2008286914B2 (en) * | 2007-08-13 | 2014-10-02 | Ohemo Life Sciences Inc. | Abuse resistant drugs, method of use and method of making |
| KR101616246B1 (ko) | 2008-01-25 | 2016-05-02 | 그뤼넨탈 게엠베하 | 약제학적 투여형 |
| AU2009243681B2 (en) | 2008-05-09 | 2013-12-19 | Grunenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
| CA2751667C (en) | 2009-02-06 | 2016-12-13 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
| NZ597283A (en) | 2009-06-24 | 2013-07-26 | Egalet Ltd | Controlled release formulations |
| TWI473628B (zh) | 2009-07-22 | 2015-02-21 | 用於對氧化敏感之類鴉片藥劑之抗破壞劑型 | |
| WO2011009602A1 (en) | 2009-07-22 | 2011-01-27 | Grünenthal GmbH | Hot-melt extruded controlled release dosage form |
| CN103002881B (zh) | 2010-05-10 | 2015-09-02 | 欧洲凯尔特公司 | 载有活性剂的颗粒与额外活性剂的组合 |
| CA2798884C (en) | 2010-05-10 | 2016-09-13 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
| AU2011252039B2 (en) * | 2010-05-10 | 2014-06-12 | Euro-Celtique S.A. | Pharmaceutical compositions comprising hydromorphone and naloxone |
| WO2012028318A1 (en) | 2010-09-02 | 2012-03-08 | Grünenthal GmbH | Tamper resistant dosage form comprising an anionic polymer |
| CA2808219C (en) | 2010-09-02 | 2019-05-14 | Gruenenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
| EP2635247B1 (en) | 2010-11-04 | 2016-12-14 | AbbVie Inc. | Method for producing monolithic tablets |
| US20120202838A1 (en) * | 2010-11-04 | 2012-08-09 | Abbott Laboratories | Drug formulations |
| GB201020895D0 (en) * | 2010-12-09 | 2011-01-26 | Euro Celtique Sa | Dosage form |
| AR084620A1 (es) * | 2010-12-28 | 2013-05-29 | Euro Celtique Sa | Una combinacion de un agonista opiaceo y un antagonista opiaceo en el tratamiento de la enfermedad de parkinson |
| AU2012289764B2 (en) | 2011-07-29 | 2017-03-02 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| ES2648129T3 (es) | 2011-07-29 | 2017-12-28 | Grünenthal GmbH | Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento |
| CA2847611A1 (en) * | 2011-09-16 | 2013-03-21 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| AR088250A1 (es) * | 2011-10-06 | 2014-05-21 | Gruenenthal Gmbh | Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide |
| US20130129826A1 (en) * | 2011-11-17 | 2013-05-23 | Gruenenthal Gmbh | Tamper-resistant oral pharmaceutical dosage form comprising opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer |
| US20130225697A1 (en) | 2012-02-28 | 2013-08-29 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| PL2838512T3 (pl) | 2012-04-18 | 2018-12-31 | Grünenthal GmbH | Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| AU2013285988A1 (en) | 2012-07-06 | 2015-02-12 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
| BR112015000320B1 (pt) | 2012-07-12 | 2023-03-07 | SpecGx LLC | Composições farmacêuticas dissuasivas de abuso e seu processo de preparação |
| CA2881144A1 (en) * | 2012-11-09 | 2014-05-09 | Purdue Pharma | Pharmaceutical compositions comprising hydromorphone and naloxone |
| US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| JP6466417B2 (ja) | 2013-05-29 | 2019-02-06 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形 |
| AU2014273227B2 (en) * | 2013-05-29 | 2019-08-15 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
| JP6449871B2 (ja) | 2013-07-12 | 2019-01-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エチレン−酢酸ビニルポリマーを含有する改変防止剤形 |
| CA3042642A1 (en) * | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| WO2015071380A1 (en) | 2013-11-13 | 2015-05-21 | Euro-Celtique S.A. | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome |
| WO2015071248A1 (en) | 2013-11-15 | 2015-05-21 | Synthon B.V. | Abuse-proofed extended release pharmaceutical composition comprising tapentadol |
| EP3073994A1 (en) | 2013-11-26 | 2016-10-05 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| JP6403780B2 (ja) * | 2013-12-17 | 2018-10-10 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド | 押出成形された持続放出性乱用抑止性丸剤 |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2015089530A1 (de) * | 2013-12-20 | 2015-06-25 | G.L. PHARMA GmbH | Orale darreichungsform mit verzögerter freisetzung enthaltend morphin und naloxon |
| CA2847781C (en) * | 2014-03-28 | 2019-03-12 | Purdue Pharma | Reducing drug liking in a subject |
| EP3142646A1 (en) | 2014-05-12 | 2017-03-22 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| EA201692388A1 (ru) | 2014-05-26 | 2017-05-31 | Грюненталь Гмбх | Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы |
| PT3164117T (pt) | 2014-07-03 | 2023-12-12 | SpecGx LLC | Formulações de libertação imediata de dissuasão de abuso compreendendo polissacáridos não celulósicos |
| CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| WO2016064873A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| BR112017021475A2 (pt) | 2015-04-24 | 2018-07-10 | Gruenenthal Gmbh | forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente |
| US20160310437A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant fixed dose combination providing fast release of two drugs from particles |
| CA2983640A1 (en) | 2015-04-24 | 2016-10-27 | Grunenthal Gmbh | Tamper-resistant fixed dose combination providing fast release of two drugs from different particles |
| MX2017013643A (es) | 2015-04-24 | 2018-03-08 | Gruenenthal Gmbh | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz. |
| AU2016293508A1 (en) * | 2015-07-10 | 2018-02-01 | Sun Pharma Advanced Research Company Ltd. | Multiple pill abuse-resistant immediate release solid dosage form of hydrocodone |
| WO2017042325A1 (en) | 2015-09-10 | 2017-03-16 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| MX383740B (es) | 2016-05-13 | 2025-03-14 | Merck Patent Gmbh | Composición de extrusión fundida en caliente que usa un excipiente compresible directo como plastificante. |
| AU2018390826B2 (en) | 2017-12-20 | 2024-09-12 | Purdue Pharma L.P. | Abuse deterrent morphine sulfate dosage forms |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| WO2020068510A1 (en) | 2018-09-25 | 2020-04-02 | SpecGx LLC | Abuse deterrent immediate release capsule dosage forms |
| EP3698776A1 (en) | 2019-02-19 | 2020-08-26 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| KR20240095253A (ko) * | 2021-10-27 | 2024-06-25 | 오11 바이오메디컬 게엠베하 | Co2의 제어된 생체내 흡수를 위한 코팅된 활성 성분 제형 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2653337B1 (fr) | 1989-10-23 | 1992-02-07 | Dow Corning Sa | Element a liberation prolongee et procede pour le fabriquer. |
| US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| US6488961B1 (en) * | 1996-09-20 | 2002-12-03 | Ethypharm, Inc. | Effervescent granules and methods for their preparation |
| DE19740983A1 (de) | 1997-09-18 | 1999-04-08 | Warner Lambert Co N D Ges D St | Verfahren zur Erschwerung der Extraktion von Wirkstoffen aus Tabletten |
| EP1183014B1 (en) | 1999-06-14 | 2003-10-08 | Cosmo S.p.A. | Controlled release and taste masking oral pharmaceutical compositions |
| EP2092936B1 (en) | 2000-02-08 | 2013-03-20 | Euro-Celtique S.A. | Tamper-resistant oral opioid agonist formulations |
| US20030068375A1 (en) * | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
| BR0212019A (pt) | 2001-08-06 | 2005-08-09 | Euro Celtique Sa | Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem |
| PT1441700E (pt) | 2001-10-15 | 2007-10-29 | Ferring Bv | Método para a preparação de uma composição compreendendo ácido 5-aminosalicílico para uso em tratamento de colites ulcerosas ou da doença de crohn |
| HUE032656T2 (en) * | 2002-04-05 | 2017-10-30 | Euro Celtique Sa | Pharmaceutical composition containing oxicodone and naloxone |
| CA2499994C (en) * | 2002-09-23 | 2012-07-10 | Verion, Inc. | Abuse-resistant pharmaceutical compositions |
| EP1613333A1 (en) | 2003-04-04 | 2006-01-11 | Pharmacia Corporation | Oral extended release compressed tablets of multiparticulates |
| DE10336400A1 (de) * | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| NZ545202A (en) | 2003-08-06 | 2010-03-26 | Gruenenthal Chemie | Abuse-proofed dosage form comprising opiods and a high molecular weight polyethylene oxide |
| GB0403098D0 (en) | 2004-02-12 | 2004-03-17 | Euro Celtique Sa | Extrusion |
| TWI350762B (en) * | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
| GB2418854B (en) | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
| DE102004062475A1 (de) | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
| GEP20105052B (en) * | 2005-01-28 | 2010-07-26 | Euro Celtique Sa | Alcohol resistant dosage forms |
| US20070026025A1 (en) | 2005-04-12 | 2007-02-01 | Aquegel Cosmetics, Llc | Topical ointment and method for making and using same |
| US20070020339A1 (en) | 2005-07-20 | 2007-01-25 | Pharmorx Inc. | Compositions and methods for controlling abuse of medications |
| DE102005047561A1 (de) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
| WO2007068615A2 (en) | 2005-12-14 | 2007-06-21 | F. Hoffmann-La Roche Ag | Hcv prodrug formulation |
| EP1813276A1 (en) | 2006-01-27 | 2007-08-01 | Euro-Celtique S.A. | Tamper resistant dosage forms |
| US7799790B2 (en) * | 2006-07-20 | 2010-09-21 | Helm Ag | Amorphous aripiprazole and process for the preparation thereof |
| EP1935405A1 (en) | 2006-12-22 | 2008-06-25 | LEK Pharmaceuticals D.D. | Orally disintegrating tablets |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| GB2447898B (en) | 2007-03-24 | 2011-08-17 | Reckitt Benckiser Healthcare | A tablet having improved stability with at least two actives |
| CN102203169B (zh) * | 2008-11-12 | 2013-08-28 | 阿克佐诺贝尔国际涂料股份有限公司 | 窄粒度分布的聚合物分散体 |
| DE102009015702A1 (de) | 2009-03-31 | 2010-10-07 | Ratiopharm Gmbh | Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung |
| GB201020895D0 (en) | 2010-12-09 | 2011-01-26 | Euro Celtique Sa | Dosage form |
-
2009
- 2009-06-05 GB GBGB0909680.1A patent/GB0909680D0/en not_active Ceased
-
2010
- 2010-06-07 NZ NZ596879A patent/NZ596879A/xx not_active IP Right Cessation
- 2010-06-07 WO PCT/GB2010/050948 patent/WO2010140007A2/en not_active Ceased
- 2010-06-07 SG SG2011089273A patent/SG176304A1/en unknown
- 2010-06-07 JP JP2012513685A patent/JP5635082B2/ja not_active Expired - Fee Related
- 2010-06-07 EA EA201171389A patent/EA022801B1/ru not_active IP Right Cessation
- 2010-06-07 KR KR1020127000058A patent/KR101816130B1/ko not_active Expired - Fee Related
- 2010-06-07 EP EP10725263.7A patent/EP2437729B1/en active Active
- 2010-06-07 MY MYPI2011005869A patent/MY173629A/en unknown
- 2010-06-07 MX MX2011012929A patent/MX2011012929A/es active IP Right Grant
- 2010-06-07 CN CN2010800344131A patent/CN102481260A/zh active Pending
- 2010-06-07 CA CA2764517A patent/CA2764517C/en not_active Expired - Fee Related
- 2010-06-07 SG SG10201402810XA patent/SG10201402810XA/en unknown
- 2010-06-07 CN CN201610970584.4A patent/CN106667919A/zh active Pending
- 2010-06-07 US US13/376,113 patent/US9814679B2/en active Active
- 2010-06-07 ES ES10725263T patent/ES2713957T3/es active Active
- 2010-06-07 BR BRPI1012004A patent/BRPI1012004A2/pt not_active Application Discontinuation
- 2010-06-07 AU AU2010255502A patent/AU2010255502B2/en not_active Ceased
-
2011
- 2011-12-04 IL IL216748A patent/IL216748A0/en unknown
- 2011-12-14 ZA ZA2011/09221A patent/ZA201109221B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010140007A2 (en) | 2010-12-09 |
| ES2713957T3 (es) | 2019-05-24 |
| NZ596879A (en) | 2013-06-28 |
| WO2010140007A9 (en) | 2012-01-19 |
| MX2011012929A (es) | 2012-04-20 |
| WO2010140007A3 (en) | 2011-11-17 |
| EP2437729B1 (en) | 2019-01-23 |
| KR101816130B1 (ko) | 2018-01-08 |
| CA2764517A1 (en) | 2010-12-09 |
| SG176304A1 (en) | 2012-01-30 |
| KR20120026595A (ko) | 2012-03-19 |
| EA022801B1 (ru) | 2016-03-31 |
| EA201171389A1 (ru) | 2012-05-30 |
| ZA201109221B (en) | 2012-08-29 |
| SG10201402810XA (en) | 2014-08-28 |
| CN106667919A (zh) | 2017-05-17 |
| JP2012528845A (ja) | 2012-11-15 |
| JP5635082B2 (ja) | 2014-12-03 |
| CA2764517C (en) | 2017-07-04 |
| US20120135075A1 (en) | 2012-05-31 |
| IL216748A0 (en) | 2012-02-29 |
| MY173629A (en) | 2020-02-12 |
| AU2010255502A1 (en) | 2012-01-12 |
| US9814679B2 (en) | 2017-11-14 |
| GB0909680D0 (en) | 2009-07-22 |
| CN102481260A (zh) | 2012-05-30 |
| EP2437729A2 (en) | 2012-04-11 |
| AU2010255502B2 (en) | 2016-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1012004A2 (pt) | "forma farmacêutica" | |
| CY2018030I1 (el) | Φαρμακοτεχνικη μορφη 514 | |
| BR112012010595A2 (pt) | "dispensdor" | |
| BR112012012872A2 (pt) | "pirrolindinas de espiroindolinona" | |
| BRPI1011813A2 (pt) | "inalador" | |
| BRPI1008023A2 (pt) | forma de dosagem sólida | |
| DK3097925T3 (da) | Farmaceutisk sammensætning | |
| BRPI0920521A2 (pt) | combinação farmacêutica | |
| BRPI1010909A2 (pt) | "inseticida arilpirrolinas" | |
| BRPI1004940A2 (pt) | composição farmacêutica | |
| EP2471786A4 (en) | aminopyrazole derivative | |
| SMT201700095B (is) | Composizioni farmaceutiche per inalazione | |
| BR112012007164A2 (pt) | "veículo" | |
| BRPI1013030A2 (pt) | "aquecedores" | |
| BRPI1015939A2 (pt) | composição farmacêutica | |
| FR2944062B1 (fr) | Injecteur d'ergols | |
| BRPI0922653A2 (pt) | preparação farmacêutica | |
| BRPI0807882A2 (pt) | Forma de dosagem | |
| SMT201600041B (it) | Agenti terapeutici 713 | |
| BR112012003149A2 (pt) | composição farmacêutica | |
| EP2628733A4 (en) | ACYLBENZEN DERIVATIVE | |
| BRPI1009730A2 (pt) | "recipiente" | |
| EP2502909A4 (en) | aminopyridine derivative | |
| MA30860B1 (fr) | Myrtillier denomme "c97-390" | |
| BRPI1013017A2 (pt) | "17beta-alquil-17alfa-óxi-estratrienos" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: EURO-CELTIQUE S.A. (LU) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |